MS Drugs Flashcards
interferons act where
periphery and BBB
interferon MOA
inhibit T cells, dendritic cells
inhibit BBB penetration by decreasing MMP
efficacy reduced by neutralizing antibodies
glatiramer acetate acts where
periphery
glatiramer acetate MOA
decreased T cell activation through dendritic cell modulation
fingolomod acts where
periphery and CNS
fingolomod MOA
S1P receptor agonist
stimulates oligodendrocyte survival / remyelination in CNS
blocks movement of T cells out of lymph nodes
what is PML
progressive multifocal leukoencephalopathy
potentially lethal brain infection
drugs with increased risk of PML
fingolomod
natalizumab
fumarates
natalizumab acts where
periphery and BBB
natalizumab MOA
MAB specific for alpha 4 integrin
inhibits VLA-4 binding and interferes with B and T cell movement into CNS
- effects could be limited by neutralizing antibodies
mitoxantrone acts where
periphery
mitoxantron MOA
cytotoxic effect
reduces the number of lymphocytes
teriflunomide acts where
periphery
teriflunomide MOA
cytotoxic effect
inhibits proliferation of lymphocytes (B and T cells)
dimethyl fumarate
diroximel fumarate
monomethyl fumarate
act where
periphery and CNS
fumarates MOA
metabolized by esterases
suppress activated T cells
promote remyelination
activate Nrf2 mediated antioxidant response and antiinflammatory pathways
siponimod, ozanimod, ponesimod location
periphery and CNS
siponimod, ozanimod, ponesimod MOA
S1P agonists
oligodendrocyte survival, remyelination
interfere with lymphocyte movement out of lymphoid organs
cladribine location
periphery
cladribine MOA
cytotoxic effect , results in lymphocyte depletion
rituximab (Ocrelizumab) location
periphery
rituximab MOA
targets CD20, a B cell marker
- limited by neutralizing antibodies